Design, Synthesis, In Vitro Biological Evaluation, and In Silico Studies of Novel Imidazo[4,5‐ b ]Pyridine‐Acrylonitrile‐Based Derivatives as VEGFR‐2 Inhibitors Against Breast Cancer and Hepatocellular Carcinoma
Drug Development Research · 2026-11 · 87 (7)
DOI: 10.1002/ddr.70385 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 15.09.2026. Verfasst von Lamia W Mohamed und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Breast Neoplasms, Liver Neoplasms, Antineoplastic Agents. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Vascular endothelial growth factor receptor‐2 (VEGFR‐2) is a vital mediator of angiogenesis. Therefore, VEGFR‐2 inhibition is considered a promising therapeutic target to combat cancer. In the present study, a series of 22 imidazo[4,5‐ b ]pyridine‐acrylonitrile‐based derivatives was designed and synthesized. All compounds were evaluated for their VEGFR‐2 inhibitory activity. Seven of the tested compounds showed high inhibitory activity against VEGFR‐2 with IC 50 (0.029–0.087 µM) compared to reference drug sorafenib IC 50 = 0.091 µM. Four of these derivatives were selected for in vitro cytotoxic activity against breast cancer (MCF‐7) and hepatocellular (HepG2) carcinoma cell lines, showing IC 50 (0.073–0.196 µM) and (0.20–0.21 µM), respectively, relative to sorafenib IC 50 0.16 and 0.19 µM, respectively. Compound 2f exhibiting a superior VEGFR‐2 inhibition (IC 50 = 0.029 µM compared to sorafenib IC 50 = 0.091 µM) and cytotoxicity against MCF‐7 and HepG2 (IC 50 = 0.073 µM and IC 50 = 0.09 µM, respectively), was subjected to cell cycle analysis, apoptosis assay, and molecular modeling studies, which strongly supported the results. It caused cell cycle arrest at G2/M phase by 13.67% and a promising apoptosis induction. 2f exhibited a promising binding score and pose inside the VEGFR‐2 active sites. It also showed a good safety profile with a moderate selectivity index. Based on the prediction of physicochemical and pharmacokinetic properties for 2f , it showed excellent prediction results to be orally bioavailable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt.
- Department of Cardiology, Sarver Heart Center, University of Arizona, Tucson, Arizona, USA.
ORCID-Profile: Lamia W Mohamed, Ayman B Farag
Zitieren
APA
Mohamed, L. W., Saadeldin, A. A., & Farag, A. B. (2026). Design, Synthesis, In Vitro Biological Evaluation, and In Silico Studies of Novel Imidazo[4,5‐ b ]Pyridine‐Acrylonitrile‐Based Derivatives as VEGFR‐2 Inhibitors Against Breast Cancer and Hepatocellular Carcinoma. Drug Development Research, 87(7). https://doi.org/10.1002/ddr.70385
Vancouver
Mohamed LW, Saadeldin AA, Farag AB. Design, Synthesis, In Vitro Biological Evaluation, and In Silico Studies of Novel Imidazo[4,5‐ b ]Pyridine‐Acrylonitrile‐Based Derivatives as VEGFR‐2 Inhibitors Against Breast Cancer and Hepatocellular Carcinoma. Drug Development Research. 2026;87(7). doi:10.1002/ddr.70385
BibTeX
@article{Mohamed2026,
author = {Mohamed, Lamia W and Saadeldin, Ahmed A and Farag, Ayman B},
title = {Design, Synthesis, In Vitro Biological Evaluation, and In Silico Studies of Novel Imidazo[4,5‐ b ]Pyridine‐Acrylonitrile‐Based Derivatives as VEGFR‐2 Inhibitors Against Breast Cancer and Hepatocellular Carcinoma},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {7},
doi = {10.1002/ddr.70385}
}
EUVIMED